國家衛生研究院 NHRI:Item 3990099045/3236

NHRI > National Institute of Infectious Diseases and Vaccinology > Charles Dwo-Yuan Sia(2006-2014) > Periodical Articles > Item 3990099045/3236

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/3236

Title:	The development and application of HLA tetramers in the detection, characterization and therapy of type 1 diabetes mellitus
Authors:	Chen, HW;Liu, SJ;Chong, P;Sia, C
Contributors:	Vaccine Research and Development Center
Abstract:	Islet antigens are presented by human leukocyte antigen (HLA) class I and II molecules and are recognized by CD8+ and CD4+ autoreactive T cells in type 1 diabetic individuals. Early identification of individuals at risk for the disease by detection of these antigens and the autoreactive cells themselves is essential for understanding pathogenesis and for intervention at an early stage to prevent ongoing beta-cell destruction. However, the methods of identifying autoimmune development at an early stage have appeared to be limited because of the heterogeneity of the disease. The appearance of autoantibodies in preclinical type 1 diabetes mellitus (T1DM) does not follow specific patterns and depends on patient characteristics such as age. Also, results obtained with cytokine assays revealed that the number of islet antigen-responsive T cells present in the pool of peripheral blood mononuclear cells (PBMC) of non-diabetic individuals is highly variable and can be similar to that assayed in diabetics. Therefore, new identification and detection methods are needed. In this context, the use of HLA epitopes to generate stable HLA epitope tetramers has recently proved to be a promising approach to the detection of autoreactive T cells in antigen-stimulated PBMC cultures from diabetic and pre-diabetic subjects. HLA class II tetramers have been found to be capable not only of detecting TCRαβ of different avidities for a common ligand, e.g. GAD65555-567(mimitope), but also of inducing apoptosis in lymphocytes with high TCRαβ avidity for this ligand. This observation even opens up a potential application of HLA class II tetramers as therapeutic agents for immune intervention in T1DM.
Date:	2007-03
Relation:	Review of Diabetic Studies. 2007 Mar;4(1):56-61.
Link to:	http://dx.doi.org/10.1900/RDS.2007.4.56
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=34548833288
Appears in Collections:	[Charles Dwo-Yuan Sia(2006-2014)] Periodical Articles [Pele Choi-Sing Chong] Periodical Articles [Shih-Jen Liu] Periodical Articles [Hsin-Wei Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP34548833288.pdf		310Kb	Adobe PDF	909	View/Open

Loading...